Skip to main content

Table 1 Characteristics of cohort at time of entry into the cohort

From: Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time

 

(N = 402)

Mean age, years (SD)

29.7 (9.4)

Median age of diagnosis, years (IQR)

1.5 (8)

Gender, % Female (N)

48.8 (196)

Race, % Caucasian (N)

94.3 (379)

Ethnicity, % Hispanic (N)

1.9 (7)

f508del status

 Homozygous, % (N)

52.4 (200)

 Heterozygous, % (N)

39.0 (149)

 Other, % (N)

8.6 (33)

CFTR Mutation Classification ad

 Minimal, % (N)

71.7 (274)

 Residual, % (N)

10.7 (41)

 Unclassified, % (N)

17.5 (67)

FEV1, % predicted (SD)d

63.5 (26.0)

Co-morbidities

 CF-related diabetes bd, % (N)

28.0 (109)

 Pancreatic insufficiency cd, % (N)

86.3 (308)

Inhaled Antibiotic Used

49.5 (147)

Microbiology

 Any form of Pseudomonas isolated, % (N)

64.2 (238)

 Mucoid Pseudomonas phenotype, % (N)

48.0 (178)

  1. SD standard deviation, IQR inter quartile range
  2. aMinimal: Both alleles containing mutations resulting in minimal CFTR function (Class 1, 2, or 3); Residual: at least one allele containing mutation resulting in partial CFTR function (Class 4 or 5); Unclassified: at least one allele with unknown CFTR function and if other allele function known, mutation resulting in minimal CFTR function
  3. bCF-related diabetes: use of insulin
  4. cPancreatic insufficiency: use of pancreatic enzymes
  5. dMissing data (N, %): CFTR Mutation Classification (20, 5.0%), FEV1 (47, 11.7%), CFRD (12, 3.0%), PI (45, 11.2%), Inhaled antibiotic use (105, 26%)